China's pharmaceutical industry generated over 1.8 trillion yuan in revenue. The market is dominated by chemical drugs, yet traditional medicine still accounts for more than a quarter of all sales.
Key Takeaways
- There are 13,000 pharmaceutical companies in China employing 5.5 million people in 2022
- China's pharmaceutical market revenue reached 1.89 trillion yuan in 2022, marking a 5.52% year-on-year increase
- China produced 48,000 tons of APIs in 2022, up 4% YoY
- R&D expenditure in China's pharma industry was 180 billion yuan in 2022, up 12%
- NMPA inspections on 1,500 firms, 80% compliant in 2022
- Pharma exports from China totaled 152 billion USD in 2022, up 10.3%
China’s pharmaceutical industry saw strong growth, driven by rising investment and expanding domestic production.
Related reading
01 · Category
Companies26 stats
01
There are 13,000 pharmaceutical companies in China employing 5.5 million people in 2022
02
Top 10 pharma companies by revenue: Sinopharm 300 billion yuan in 2022
03
Hengrui Pharma R&D spend 12 billion yuan, revenue 240 billion in 2022
04
Fosun Pharma revenue 50 billion yuan, international sales 10 billion 2022
05
China Resources Pharma revenue 180 billion yuan in 2022
06
Shanghai Pharma sales 280 billion yuan, hospitals 500+ owned 2022
07
BeiGene market cap 500 billion yuan, 10+ innovative drugs 2022
08
Innovent Bio revenue 10 billion yuan, up 40% in 2022
09
WuXi AppTec CRO revenue 30 billion yuan in 2022
10
Hansoh Pharma revenue 20 billion yuan, oncology focus 2022
11
Listed pharma companies 300+ on SSE/SZSE in 2022
12
Foreign pharma firms in China 200+ JVs in 2022
13
CMOs/CDMOs 500 firms serving global market 2022
14
Top 100 pharma by sales revenue totaled 1.2 trillion yuan 2022
15
Employment growth in pharma 5% to 5.8 million in 2022
16
Women comprise 45% of pharma workforce in China 2022
17
R&D personnel 15% of total workforce in top firms 2022
18
Mergers & acquisitions in pharma 150 deals worth 100 billion yuan 2022
19
Unicorns in biotech 50 valued over 500 billion yuan total 2022
20
State-owned enterprises 40% market share in distribution 2022
21
Private firms 60% of innovative drug developers 2022
22
Digital pharma startups 1,000+ funded 50 billion yuan 2022
23
Vaccine makers Sinovac/BioNTech sales 20 billion yuan 2022
24
API giants like North China Pharma output 100,000 tons 2022
25
Generics leaders like Huahai Pharma exports 2 billion USD 2022
26
TCM leaders Tasly revenue 15 billion yuan 2022
Interpretation
Companies Interpretation
China’s pharmaceutical sector is dominated by a highly concentrated company base, with 13,000 firms employing 5.5 million people in 2022 while the biggest players reach tens to hundreds of billions of yuan in revenue, such as Sinopharm at 300 billion yuan and China Resources Pharma at 180 billion yuan, underscoring how leading companies drive most market scale.
02 · Category
Market Size30 stats
01
China's pharmaceutical market revenue reached 1.89 trillion yuan in 2022, marking a 5.52% year-on-year increase
02
The compound annual growth rate (CAGR) of China's pharma market from 2017 to 2022 was 7.2%
03
In 2023, China's biopharmaceutical market segment grew by 15% to exceed 400 billion yuan
04
Traditional Chinese medicine (TCM) sales accounted for 28% of total pharma revenue in China in 2022, totaling 534 billion yuan
05
Chemical drug sales in China hit 1.05 trillion yuan in 2022, representing 55% of the market
06
China's retail pharmacy market size was 1680 billion yuan in 2022 with 8.5% growth
07
Hospital drug sales in China reached 1.2 trillion yuan in 2022, down 1.2% YoY
08
The oncology drug market in China grew 12% to 130 billion yuan in 2022
09
China's vaccine market revenue was 85 billion yuan in 2022, up 20% YoY
10
Consumer health products market in China reached 320 billion yuan in 2022, CAGR 8.5% from 2018-2022
11
Medical device market in pharma-related segments hit 380 billion yuan in 2022
12
Innovative drug sales grew 22% to 180 billion yuan in 2022
13
Generics accounted for 65% of China's pharma volume but 40% of value in 2022
14
OTC drug market size was 120 billion yuan in 2022, up 6%
15
Biosimilars market in China expanded to 25 billion yuan in 2022, CAGR 30%
16
Rare disease drug market reached 15 billion yuan in 2022, growing 18%
17
Digital health pharma integration market valued at 50 billion yuan in 2022
18
Pharma e-commerce sales hit 200 billion yuan in 2022, up 25%
19
Projected pharma market size for China in 2025 is 2.5 trillion yuan, CAGR 7%
20
Antivirals segment revenue was 90 billion yuan in 2022
21
Cardiovascular drugs market 250 billion yuan in 2022
22
Diabetes drug sales 150 billion yuan in 2022, up 10%
23
Autoimmune drugs market 80 billion yuan in 2022, CAGR 15%
24
Respiratory drugs 110 billion yuan in 2022
25
Gastroenterology drugs 70 billion yuan in 2022
26
Ophthalmology pharma market 40 billion yuan in 2022
27
Dermatology drugs 60 billion yuan in 2022, up 8%
28
CNS drugs market 200 billion yuan in 2022
29
Pain management drugs 55 billion yuan in 2022
30
Pharma market per capita spending in China was 1,300 yuan in 2022
Interpretation
Market Size Interpretation
China’s overall pharmaceutical market reached 1.89 trillion yuan in 2022 and continued steady expansion with a 7.2% CAGR from 2017 to 2022, showing the market size for pharma is growing while biopharmaceuticals surged 15% in 2023 to over 400 billion yuan.
03 · Category
Production25 stats
01
China produced 48,000 tons of APIs in 2022, up 4% YoY
02
China manufactured 2.5 billion packs of finished dosage forms in 2022
03
There were 5,200 pharmaceutical manufacturing enterprises in China in 2022
04
Injection production capacity reached 20 billion units annually in China by 2022
05
Tablet production output was 1.2 trillion pieces in 2022
06
Capsule manufacturing hit 500 billion units in 2022
07
Oral liquid production volume 15 billion liters in 2022
08
Powder injections produced 8 billion vials in 2022
09
China’s API export volume was 350,000 tons in 2022
10
Over 90% of penicillin APIs worldwide produced in China in 2022
11
Vitamin C production capacity 150,000 tons/year in China 2022
12
Ibuprofen API output 50,000 tons in 2022
13
Paracetamol production 120,000 tons in 2022
14
China has 1,200 sterile injection lines approved in 2022
15
Biologic drug production facilities numbered 300 in China 2022
16
Cell therapy manufacturing sites reached 50 in 2022
17
Vaccine production capacity 3 billion doses/year in China 2022
18
mRNA vaccine production lines 10 operational in 2022
19
Chemical drug production value 1.1 trillion yuan in 2022
20
Biopharma manufacturing output up 18% to 250 billion yuan 2022
21
TCM raw material processing 2 million tons in 2022
22
Granules TCM production 1.5 million tons 2022
23
China’s pharma production PMI averaged 52.5 in 2022
24
Capacity utilization rate in pharma manufacturing 78% in 2022
25
New drug production lines approved 150 in 2022
Interpretation
Production Interpretation
For the production side of China’s pharmaceutical industry, 2022 output scaled sharply with 1.2 trillion tablets and 500 billion capsules produced, alongside an injection capacity of 20 billion units annually, underscoring how volume manufacturing is the core strength of the sector.
More related reading
04 · Category
R&d24 stats
01
R&D expenditure in China's pharma industry was 180 billion yuan in 2022, up 12%
02
China filed 15,000 pharma patents in 2022, ranking 2nd globally
03
Clinical trials approved 1,200 for innovative drugs in 2022
04
Biopharma R&D investment grew 20% to 90 billion yuan in 2022
05
China approved 81 novel drugs in 2022
06
Phase III trials ongoing for 500+ drugs in China 2022
07
R&D staff in pharma reached 800,000 in 2022
08
AI in drug discovery investments 10 billion yuan in 2022
09
Gene therapy trials 50 approved in 2022
10
CAR-T cell therapy INDs 20 filed in 2022
11
mRNA tech R&D funding 15 billion yuan in 2022
12
ADC drug pipeline 100+ in development 2022
13
China’s pharma R&D intensity (R&D/sales) 9.5% in 2022
14
CRO industry revenue 120 billion yuan in 2022
15
CDMO services grew 25% to 80 billion yuan 2022
16
National key R&D projects funded 50 pharma ones in 2022, 20 billion yuan
17
University pharma research output 5,000 papers in 2022
18
Big pharma R&D centers in China 200+ in 2022
19
Stem cell research grants 5 billion yuan in 2022
20
Precision medicine R&D spend 30 billion yuan 2022
21
Vaccine R&D pipeline 300 candidates in 2022
22
Oncology drug INDs 400 filed in 2022
23
Autoimmune R&D investment 25 billion yuan 2022
24
CNS disorder trials 200 new in 2022
Interpretation
R&d Interpretation
In 2022, China’s pharmaceutical R&D surged with 180 billion yuan in spending and a 20% jump in biopharma investment to 90 billion yuan, alongside 15,000 filed patents and 81 novel drugs approved, showing a rapid expansion of innovation capacity from lab work to clinical development.
05 · Category
Regulatory1 stats
01
NMPA inspections on 1,500 firms, 80% compliant in 2022
Interpretation
Regulatory Interpretation
In 2022, the NMPA inspected 1,500 firms and found only 80% compliance, signaling ongoing regulatory pressure and a meaningful compliance gap in China’s pharmaceutical sector.
06 · Category
Trade25 stats
01
Pharma exports from China totaled 152 billion USD in 2022, up 10.3%
02
Pharma imports to China reached 70 billion USD in 2022
03
APIs exported 420,000 tons worth 18 billion USD in 2022
04
Finished drugs export value 45 billion USD in 2022
05
Top export market US took 20% of China pharma exports in 2022
06
EU imported 15 billion USD pharma from China in 2022
07
India sourced 30% of its APIs from China in 2022
08
China’s trade surplus in pharma 82 billion USD in 2022
09
Biologics exports grew 25% to 8 billion USD 2022
10
Vaccine exports 5 billion doses worth 3 billion USD in 2022
11
TCM exports reached 4 billion USD in 2022, up 12%
12
Medical devices pharma-related exports 20 billion USD 2022
13
Patent drug imports 40 billion USD in 2022
14
Zero-tariff imports from ASEAN pharma 2 billion USD 2022
15
Belt and Road pharma exports 30 billion USD in 2022
16
Online pharma exports via e-commerce 5 billion USD 2022
17
Export growth to Africa 15% for pharma in 2022
18
Latin America pharma imports from China 10 billion USD 2022
19
Middle East pharma exports 7 billion USD from China 2022
20
Russia pharma imports from China up 20% to 4 billion USD 2022
21
Japan pharma trade with China balanced at 6 billion USD each way 2022
22
Korea imported 5 billion USD APIs from China 2022
23
Australia pharma imports from China 3 billion USD 2022
24
Pharma firms with export licenses 2,500 in China 2022
25
China ranked 1st global API exporter with 45% share in 2022
Interpretation
Trade Interpretation
In 2022, China’s pharmaceutical trade showed strong momentum with exports rising 10.3% to 152 billion USD while imports reached 70 billion USD, and APIs leading the scale at 420,000 tons worth 18 billion USD.
report visual · Projection
China’s pharma market growth and accelerating biotech momentum
China’s pharmaceutical market is expanding steadily, with biopharma growth outpacing the broader market in the latest segment data provided.
7.2 growth (%)
Start
+13.01%
CAGR · 6y
15 growth (%)
Projected
20222028
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Nathan Caldwell. (2026, February 13). China Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/china-pharmaceutical-industry-statistics
MLA
Nathan Caldwell. "China Pharmaceutical Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/china-pharmaceutical-industry-statistics.
Chicago
Nathan Caldwell. 2026. "China Pharmaceutical Industry Statistics." Gitnux. https://gitnux.org/china-pharmaceutical-industry-statistics.
Sources & references
94 datasets cited across this report · attribution is report-level